Impact of CYP2D6 Genotypes on Oxycodone in Cancer Patients
Author Information
Author(s): Aaron K. Wong, Sara Vogrin, Pal Klepstad, Justin Rubio, Le Brian, Jennifer Philip, Andrew A. Somogyi
Primary Institution: Peter MacCallum Cancer Centre
Hypothesis
Do CYP2D6 genotypes affect oxycodone dose, pharmacokinetics, pain, and adverse effects in cancer?
Conclusion
CYP2D6 genotyping did not show a benefit in oxycodone response, but monitoring noroxycodone and oxymorphone concentrations is suggested for further study.
Supporting Evidence
- Higher plasma noroxycodone concentrations were associated with higher odds of uncontrolled average pain.
- There were no differences in pain response between CYP2D6 intermediate/poor and normal metabolizers.
- Monitoring of noroxycodone and oxymorphone concentrations warrants further investigation.
Takeaway
This study looked at how different genes affect how cancer patients respond to oxycodone, a pain medicine, and found that the genes didn't really change how well the medicine worked.
Methodology
This was a multi-center prospective cohort study that included clinical data, questionnaires, and blood samples for pharmacokinetic analysis.
Potential Biases
The study's sample was heterogeneous in terms of cancer types, which could affect pain severity and opioid dosing.
Limitations
The study had a small sample size and lacked ultrarapid metabolizers, which limited the comparisons that could be made.
Participant Demographics
The study included 33 inpatients with cancer-related pain, with a median age of 63 years and 61% male.
Statistical Information
P-Value
0.05
Confidence Interval
95% CI 1.00–5.95
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website